European Journal of Cancer, 166, 219-228. ELSEVIER SCI LTD 2022, ' Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial ', European Journal of Cancer, vol. 166, pp. 219-228 . https://doi.org/10.1016/j.ejca.2022.01.031